AI Unbundles Cardiac Risk: The Next Billion-Dollar Investment

Traditional cardiac screenings are too slow. They depend on a patient showing obvious symptoms or having blunt population risk factors, meaning they frequently miss the quiet, early warnings of a major cardiovascular event. That delay between a developing problem and a diagnosis leaves a massive, underserved market that’s a perfect fit for predictive AI, which promises to get patients treated sooner and get better results. For investors trying to find the next big winner in this space, the job is to find the companies that are successfully pulling apart old-school cardiology diagnostics and plugging in smart, predictive algorithms that work inside existing hospital workflows.

The Unbundling of Cardiac Diagnostics: Predictive AI’s Ascent

The healthcare business is always breaking things apart and putting them back together, and cardiology’s turn is now. Cardiac risk assessment used to be a long chain of separate tests, usually started only after a patient complained of symptoms. Predictive AI is flipping that script, letting doctors proactively find high-risk people long before a crisis. It’s a fundamental change from reactive medicine to predictive care, a shift that smart investors have definitely noticed. Our analysis uses a proprietary scoring rubric that looks at three things we think are make-or-break for a pre-IPO AI health company: clinical validation, workflow integration, and regulatory clearance. If a company can nail all three, they have a real path to getting into the market and building a sustainable business.

Viz.ai and Tempus AI: Charting Distinct Paths to Predictive Cardiology

Two companies, Viz.ai and Tempus AI, show two very different but solid strategies for using AI in cardiology. Both are getting a lot of attention from investors, but for different reasons. Viz.ai has built its business on real-time detection and triage for acute problems, focusing mostly on stroke and pulmonary embolism. Their success comes from methodically getting one FDA 510(k) clearance after another for their AI algorithms, which you can see in the FDA 510(k) database for Viz.ai algorithms. Getting these clearances from the FDA removes a huge amount of risk and shows investors a clear commercial path for their Software as a Medical Device (SaMD) products. In practice, Viz.ai’s algorithms analyze medical images like CT scans, find potential problems, and send an alert to the right care team in minutes, which dramatically cuts down the time to treatment. This fast, integrated system solves a genuine problem in emergency care. Tiger Global leading a $100 million Series D round that valued Viz.ai at $1.2 billion shows how much investors believe in the company’s ability to deliver real, time-sensitive clinical improvements. Their initial product, detecting and triaging acute events, gets them inside a hospital’s systems, which then gives them a launchpad to expand into more predictive tools. Tempus AI is taking a completely different approach to predictive health by focusing on genomics and clinical data integration to build an unbeatable data moat. Though it’s best known for its work in oncology, Tempus is pushing hard into cardiology with key data partnerships, as detailed in its S-1 filing. Tempus’s goal is to combine huge genomic datasets with clinical records to find the genetic markers and subtle biological signals that could predict cardiac problems years before they happen. After its IPO in June 2024, Tempus AI hit a $6.1 billion valuation, which speaks to how much the market values its deep data infrastructure and AI-driven precision medicine work. While its cardiology products are at an earlier stage on the regulatory path than Viz.ai’s acute care tools, the long-term potential for creating highly personalized risk profiles is enormous. This is what an “AI-Native Company” looks like. The entire business is built from the ground up on AI and data.

The Olive AI Cautionary Tale: Workflow Without Validation is a Dead End

To really get the value of what Viz.ai and Tempus AI are doing, it’s worth looking at the smoking crater of Olive AI. Olive AI was once a hot company in administrative AI, raising over $900 million before it completely shut down. The company was all about automating back-office tasks in healthcare, promising big efficiency gains by optimizing workflows. The problem? Olive AI never delivered proven, validated results that gave health systems a reason to keep paying for it. The difference comes down to the clinical validation and regulatory clearance parts of our scoring rubric. Olive’s tools were meant to fit into hospital workflows, but they were more like simple Clinical Decision Support (CDS) tools and lacked the serious, FDA-cleared diagnostic power that builds trust and gets doctors on board. The lesson for investors is blunt: slick workflow integration is nice, but without strong, peer-reviewed clinical evidence and, for a diagnostic, FDA clearance (like a 510(k) or De Novo classification), even a mountain of cash can’t stop a company from becoming a zombie or just failing outright. Olive AI also never built a real “data moat” from proprietary, clinically useful data, which meant it couldn’t create defensible IP or make its models better without tons of manual work, causing its algorithms to drift.

Proprietary Scoring Rubric for Predictive Cardiac AI Investment

Our scoring rubric for checking out pre-IPO predictive cardiac AI companies focuses on three areas: 1. Clinical Validation (40%): I’m looking for the quality and volume of published outcomes data, independent trials, and real-world evidence (RWE). Does the AI actually improve diagnostic accuracy, cut down treatment time, or predict events with better sensitivity than the old methods? You get high marks for having papers in peer-reviewed journals and solid RWE.

1. Workflow Integration (35%): How well does the software actually plug into a hospital’s existing EHRs, imaging systems, and daily routines? How easy is it to install, how much does it disrupt doctors, and what are the adoption rates? A good “wedge product” that solves one big, expensive problem right away is often the key to getting a foot in the door for broader integration.
2. Regulatory Clearance (25%): Having an FDA 510(k) clearance, especially for a diagnostic AI, removes a huge amount of risk for an investor. Seeing a company go for a De Novo classification for a totally new kind of predictive tool, or getting a Breakthrough Device Designation, signals a smart regulatory strategy. Also, a commitment to Good Machine Learning Practice (GMLP) and a real Quality Management System (QMS / ISO 13485) are not negotiable. They’re essential for any company planning to be around for the long haul. You can see the FDA’s thinking on this in their guidance on Good Machine Learning Practice.
   

   The Investment Thesis: Look for Regulated, Integrated, and Validated Predictive AI

The next big companies in cardiac AI will be the ones that can connect raw predictive power with practical, everyday clinical use. For investors, that means looking past the AI hype and zeroing in on companies that have FDA-cleared predictive algorithms that fit cleanly into hospital EHRs. These companies are unbundling the old way of doing diagnostics by inserting intelligence at just the right points to predict heart attacks and other crises earlier than was ever possible. Viz.ai’s success in the acute care setting and Tempus AI’s long-term play on genomic data are two powerful models for this. Both companies get that clinical validation and working through the FDA are everything. On the other hand, Olive AI is a powerful reminder that all the capital in the world can’t make up for a lack of proven clinical results and regulatory planning. The growing cardiac AI market, as shown in reports like this one from the AHA, will demand solutions that are not just clever but are rigorously tested and woven into how healthcare actually gets delivered.